Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pharmaceutical Firms Add Transparency

May 7, 2007 | A version of this story appeared in Volume 85, Issue 19

Eli Lilly & Co. is launching a website to publicize all educational grant funding and other contributions it makes to U.S.-based organizations. The website will show the organizations receiving grants and how the money is being spent. The company provides money to a host of hospitals and universities doing research in disease areas, such as endocrinology, neuroscience, and oncology, in which Lilly has expertise or is developing drugs. Meanwhile, Pfizer has launched a site to list the postmarketing studies it has agreed to conduct after a drug is launched. The studies are often a requirement in FDA's approval of a drug and can be critical to understanding long-term safety.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.